Gefitinib or Carboplatin–Paclitaxel in Pulmonary AdenocarcinomaTony Mok, Masahiro Fukuoka, Yukito Ichinose et al.|New England Journal of Medicine|2009Cited by 8.2k
Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)Masahiro Fukuoka, Tony Mok, Yi‐Long Wu et al.|Journal of Clinical Oncology|2011Cited by 1.6k
Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trialManish A. Shah, Rui‐Hua Xu, Kohei Shitara et al.|Nature Medicine|2023Cited by 541
Inavolisib-Based Therapy in <i>PIK3CA</i> -Mutated Advanced Breast CancerNicholas C. Turner, Komal Jhaveri, Seock‐Ah Im et al.|New England Journal of Medicine|2024Cited by 235